文献速递糖尿病

靶向IL-2、IL-6和TYK2信号通路预防1型糖尿病的遗传学证据:一项孟德尔随机化研究

Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study.
PubMed 文献 · Diabetologia · 2024-09-13

该研究利用全基因组关联研究汇总数据,对7个潜在药物靶点基因附近的遗传多态性进行共定位和孟德尔随机化分析,发现IL2RA、IL6R、IL6ST和TYK2的遗传代理与1型糖尿病风险相关,支持靶向IL-2、IL-6和TYK2信号通路预防1型糖尿病。

要点

  • IL2RA、IL6R和IL6ST的血液表达水平与1型糖尿病易感性共享同一因果变异。
  • 遗传代理的IL2RA表达每增加1个标准差,1型糖尿病OR为0.22(95%CI 0.17,0.27)。
  • 遗传代理的IL6R和IL6ST表达每增加1个标准差,1型糖尿病OR分别为1.98和1.90。

核心结论

  • 研究结果支持靶向IL-2、IL-6和TYK2信号通路预防1型糖尿病。

研究设计与样本

  • 研究获取1型糖尿病风险、全血基因表达和血清蛋白水平的全基因组关联研究汇总统计数据,并探究7个潜在药物靶点基因附近的遗传多态性。
  • 研究采用共定位分析检验与1型糖尿病风险相关的遗传变异是否也与相关药物靶点的遗传代理相关,并采用孟德尔随机化评估关联的方向和幅度。
  • 研究还进行了限制在药物靶点基因内功能变异的孟德尔随机化分析。

主要发现

  • 共定位分析显示,IL2RA、IL6R和IL6ST的血液表达水平与对应基因附近的1型糖尿病易感性共享同一因果变异,后验概率分别为100%、96.5%和97.0%。
  • 遗传代理的IL2RA、IL6R和IL6ST基因表达每增加1个标准差,1型糖尿病OR(95%CI)分别为0.22(0.17,0.27)、1.98(1.48,2.65)和1.90(1.45,2.48)。
  • 使用错义变异时,遗传代理的TYK2表达水平与1型糖尿病风险相关,OR为0.61(95%CI 0.54,0.69)。

关键数值与推荐

  • IL2RA、IL6R和IL6ST血液表达水平与1型糖尿病易感性共享同一因果变异的后验概率分别为100%、96.5%和97.0%。
  • 遗传代理的IL2RA、IL6R和IL6ST基因表达每增加1个标准差,1型糖尿病OR(95%CI)分别为0.22(0.17,0.27)、1.98(1.48,2.65)和1.90(1.45,2.48)。
  • 使用错义变异时,遗传代理的TYK2表达水平与1型糖尿病风险相关,OR为0.61(95%CI 0.54,0.69)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to investigate the genetic evidence that supports the repurposing of drugs already licensed or in clinical phases of development for prevention of type 1 diabetes. METHODS: We obtained genome-wide association study summary statistics for the risk of type 1 diabetes, whole-blood gene expression and serum protein levels and investigated genetic polymorphisms near seven potential drug target genes. We used co-localisation to examine whether the same genetic variants that are associated with type 1 diabetes risk were also associated with the relevant drug target genetic proxies and used Mendelian randomisation to evaluate the direction and magnitude of the associations. Furthermore, we performed Mendelian randomisation analysis restricted to functional variants within the drug target genes. RESULTS: Co-localisation revealed that the blood expression levels of IL2RA (encoding IL-2 receptor subunit α [IL2RA]), IL6R (encoding IL-6 receptor [IL6R]) and IL6ST (encoding IL-6 cytokine family signal transducer [IL6ST]) shared the same causal variant with type 1 diabetes liability near the corresponding genes (posterior probabilities 100%, 96.5% and 97.0%, respectively). The OR (95% CI) of type 1 diabetes per 1-SD increase in the genetically proxied gene expression of IL2RA, IL6R and IL6ST were 0.22 (0.17, 0.27), 1.98 (1.48, 2.65) and 1.90 (1.45, 2.48), respectively. Using missense variants, genetically proxied TYK2 (encoding tyrosine kinase 2) expression levels were associated with type 1 diabetes risk (OR 0.61 [95% CI 0.54, 0.69]). CONCLUSIONS/INTERPRETATION: Our findings support the targeting of IL-2, IL-6 and TYK2 signalling in prevention of type 1 diabetes. DATA AVAILABILITY: The analysis code is available at https://github.com/jkoskenniemi/T1DSCREEN , which also includes instructions on how to download the original GWAS summary statistics.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Heikkilä TE, Kaiser EK, Lin J, et al. Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study. Diabetologia. 2024. PMID: 39271518. doi:10.1007/s00125-024-06267-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。